Accelerating AXL targeting for TNBC therapy Lohit Khera, Sima Lev

First described by electron microscopists in the early 60s the ER-Golgi contact sites in mammalian cells have remained The tyrosine kinase receptor AXL of the TAM (TYRO3, AXL and MERTK) family is considered as a promising therapeutic target for different hematological cancers and solid tumors. AXL is involved in multiple pro- tumorigenic processes including cell migration, invasion, epithelial-mesenchymal transition (EMT), and stem-ness, and recent studies demonstrated its impact on cancer metastasis and drug resistance. Extensive studies on AXL have highlighted its unique characteristics and physiological functions and suggest that targeting of AXL could be beneficial in combination with chemotherapy, radiotherapy, immunotherapy, and targeted therapy. In this mini review, we discuss possible outcomes of AXL targeting either alone or together with other therapeutic agents and emphasize its impact on triple negative breast cancer (TNBC).


Be the first to comment

Leave a Reply

Your email address will not be published.